Neda Nemat-Gorgani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Neda Nemat-Gorgani has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Ajay Subramanian
Department of Radiation Oncology, Stanford University, Stanford, CA, USA
47 shared publications - Everett J. Moding
Department of Radiation Oncology, Stanford University, Stanford, CA
47 shared publications - Matt van de Rijn
Department of Pathology, Stanford University, Stanford, California
31 shared publications - David S. Wang
Department of Radiology, Stanford University, Stanford, California
26 shared publications - Gloria L. Hwang
Division of Interventional Radiology, Stanford Health Care, Stanford, CA, United States
26 shared publications - Gregory W. Charville
Stanford University School of Medicine
26 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplementary Table S4 shows patient characteristics of surgical specimens from patients with sarcoma undergoing routine standard of care (n=44).
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplementary Table S4 shows patient characteristics of surgical specimens from patients with sarcoma undergoing routine standard of care (n=44).
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S10 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplementary Table S10 shows individual patient level clinical outcomes
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplementary Table S10 shows individual patient level clinical outcomes
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplemental Figure S5 shows impact of BO-112 and RT on intratumoral immune composition in human specimens.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplemental Figure S5 shows impact of BO-112 and RT on intratumoral immune composition in human specimens.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplemental Figure S1 shows focal RT using image guidance and treatment planning to target the tumor and spare local lymph node
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplemental Figure S1 shows focal RT using image guidance and treatment planning to target the tumor and spare local lymph node
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplemental Figure S6 shows intratumoral T cell evolution is facilitated by clonal replacement by less exhausted T cells, related to Figure 6.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplemental Figure S6 shows intratumoral T cell evolution is facilitated by clonal replacement by less exhausted T cells, related to Figure 6.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplemental Figure S2 shows intratumoral administration is necessary for optimal anti-tumor efficacy of BO-112
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplemental Figure S2 shows intratumoral administration is necessary for optimal anti-tumor efficacy of BO-112
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S1, S3, S6-9 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplementary Data is an excel file with supplementary tables S1, S3, and S6-S9 compiled. Supplemental Table 1 shows complete adverse events and relatedness to BO-112 or nivolumab by cohort. Supplemental Table 3 shows overall treatment emergent adverse events. Supplemental Table 6 shows key genes for annotation of myeloid clusters in scRNA-seq. Supplemental Table 7 shows top 100 differentially expressed genes for each myeloid cluster. Supplemental Table 8 shows annotation of T cell subsets by top differentially expressed genes. Supplemental Table 9 shows representativeness of Study Participants
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1, S3, S6-9 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplementary Data is an excel file with supplementary tables S1, S3, and S6-S9 compiled. Supplemental Table 1 shows complete adverse events and relatedness to BO-112 or nivolumab by cohort. Supplemental Table 3 shows overall treatment emergent adverse events. Supplemental Table 6 shows key genes for annotation of myeloid clusters in scRNA-seq. Supplemental Table 7 shows top 100 differentially expressed genes for each myeloid cluster. Supplemental Table 8 shows annotation of T cell subsets by top differentially expressed genes. Supplemental Table 9 shows representativeness of Study Participants
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplementary Table S5 shows patient characteristics of surgical specimens from patients with sarcoma undergoing pre-operative, hypofractionated RT alone as part of a separate Phase 2 clinical trial (NCT02701153).
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplementary Table S5 shows patient characteristics of surgical specimens from patients with sarcoma undergoing pre-operative, hypofractionated RT alone as part of a separate Phase 2 clinical trial (NCT02701153).
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Figure S7 shows clinical outcomes related to neoadjuvant RT + BO-112, related to Figure 7.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Figure S7 shows clinical outcomes related to neoadjuvant RT + BO-112, related to Figure 7.